Short-term Effect and Safety of a Single Intravitreal Brolucizumab in Refractory Neovascular Age-related Macular Degeneration

Intravitreal therapy in bilateral neovascular age-related macular degeneration.

Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration.

PURPOSE To report the change in visual acuity and central retinal thickness by optical coherence tomography (OCT) after intravitreal injections of bevacizumab for the treatment of neovascular age-related macular degeneration (AMD). METHODS A retrospective case series in a university-based practice evaluated patients with subfoveal choroidal neovascularization (CNV) due to AMD. Patients receiv...

Measurement of Choroidal Neovascular Area in Age-Related Macular Degeneration using Modified Otsu’s Thresholding Method

Introduction: Age-related Macular Degeneration (AMD) is one of the most important causes of irreversible  blindness in the developed world and  prevents the affected  person from  performing simple tasks such  as  reading,  driving  and  facial  recognition.  In  the  AMD,  new  blood  vessels  grow  underneath  the  retina  in  a  process  called  choroidal  neovascularisation  (CNV).  There  ...

Neovascular Age - Related Macular Degeneration

Intravitreal bevacizumab in the management of neovascular age-related macular degeneration: effect of baseline visual acuity.

PURPOSE To study prospectively the safety and efficacy of intravitreal bevacizumab for eyes with neovascular age-related macular degeneration with baseline visual acuity better than 70 letters (Snellen equivalent better than 20/40). METHODS Patients with treatment-naive neovascular age-related macular degeneration were categorized prospectively into three groups according to baseline visual a...